Table 1

Demographic, clinical and laboratory characteristics of patients at start of anakinra treatment† and at last follow-up‡

Characteristics	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8
Sex	F	M	F	F	F	F	F	F
Age (years)	32	27	37	26	48	54	47	66
Disease duration (months)†	44	52	5	4	31	48	139	11
Main clinical expression at disease entry	Systemic	Systemic	Systemic	Articular	Articular	Articular	Articular	Systemic
Maximal body temperature (°C)†	40	39	39	39.5	40	40	40	39
Rash†	+	+	+	+	−	+	+	+
Arthritis†	+	+	+	+	+	+	+	+
Lymphadenopathy/splenomegaly/hepatomegaly†	+/+/−	−/+/−	+/+/+	+/−/−	−/−/−	−/+/+	−/+/−	+/−/−
Serositis†	+	+	−	−	+	−	+	−
CRP (mg/dl)†	16.2	12.1	7.1	8.1	13.0	16.0	11.3	7.8
ESR (mm/h)†	72	75	93	96	30	80	100	39
Neutrophils (/mm³)†	19170	25400	17830	20350	24890	20400	14200	18900
Ferritin (ng/ml)†	993	919	1252	3293	29	323	1693	5190
AST (U/l)†	44	16	33	37	29	41	n. d.	40
ALT (U/l)†	39	7	14	22	9	69	n. d.	115
Prednisolone (mg/day)	100†	75†	50†	50†	60†	60†	50†	50†
	10‡	2.5‡	5‡	2.5‡	2‡	7‡	15‡	7.5‡
DMARD	MTX*‡	MTX*	MTX*	MTX*	MTX*	MTX*	MTX*‡	CYP* AZT* MTX*
	LFM*	LFM*	LFM*‡		CyA*	LFM*		CyA‡
Anti-TNF	ETN*	ETN*	−	−	ETN*	ETN*	ETN*	−
						IFL*
						ADM*
Follow-up on anakinra (months)	48	48	6	12	36	44	12	9

*Treatments to which the patient had not responded before starting anakinra.
ADM, adalimumab; ALT, alanine aminotransferase (normal value <34); AST, aspartate aminotransferase (normal value <35); CRP, C-reactive protein (normal value <0.5); CYP, cyclophosphamide; CyA, ciclosporin A; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; ETN, etanercept; IFL, infliximab; LFM, leflunomide; MTX, methotrexate; TNF, tumour necrosis factor.